ArticleScience (New York, N.Y.)2019
Ultrapotent chemogenetics for research and potential clinical applications.
Article in Science (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06027190 (To Investigate the Clinical Efficacy of Optical 3D Navigation Repetitive Transcranial Magnetic Stimulation), which is not on this map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Investigate the Clinical Efficacy of Optical 3D Navigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Achalasia, Optimize the Treatment Parameters, and Provide a Noninvasive Treatment Strategy for Achalasia
Who cites it
110 citing papers in PubMed.
- Overview of the DREADDs chemogenetics and the patent landscape of their actuators.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Article
- Article
- Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent.Signal transduction and targeted therapy · 2026Article
- Comparative analysis of ligand binding affinities and functional profiles at recombinant human β-adrenergic receptor subtypes 1, 2, and 3.The Journal of pharmacology and experimental therapeutics · 2026Review
- Scg2 drives corticospinal circuit reorganization with spinal premotor interneurons and astrocytes for motor recovery after stroke in mice.Nature communications · 2026Article
- Activation by Alcohol of Prefrontal Layer 5 Pyramidal Neurons Depends on Ascending Dopaminergic Input.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Sex-specific frontal cortical circuit mechanisms mediating fear extinction.bioRxiv : the preprint server for biology · 2026Article
- Rapid formation of non-spatial hippocampal representations consistent with behavioral timescale synaptic plasticity is modulated by entorhinal input.Nature communications · 2026Article
- Gene therapy for epilepsy: An emerging, promising approach for a serious neurological disorder.Journal of internal medicine · 2026Review
- The role of central versus peripheral opioid receptors in fentanyl-induced brain hypoxia.Journal of neurophysiology · 2026Article
- Live-cell physiology in human brain tissue culture-the potential, the challenges, and the lessons learned.Frontiers in cellular neuroscience · 2026Review
- Covalent anchoring of tethered ligands to chemogenetic handles for targeted in vivo neuropharmacology.STAR protocols · 2025Article
- Understanding varenicline function via key receptor and ligand interactions.Cell reports. Physical science · 2025Article
- Cortical glutamatergic and GABAergic inputs support learning-driven hippocampal stability.Science (New York, N.Y.) · 2025Article
- Bottom-up design of CaNature · 2025Article
- Convergent Control of NREM Sleep and Anesthesia by Prefrontal Layer 5 Extratelencephalic Neurons.Research square · 2025Article
- The central histaminergic system slows visual processing in the retina and lateral geniculate nucleus of awake mice.PLoS biology · 2025Article
- Circuit-selective pharmacological targeting of prefrontal cortex-projecting locus coeruleus neurons drives antinociception.Cell reports · 2025Article
- Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
Chemogenetics enables noninvasive chemical control over cell populations in behaving animals. However, existing small-molecule agonists show insufficient potency or selectivity. There is also a need for chemogenetic systems compatible with both research and human therapeutic applications. We developed a new ion channel-based platform for cell activation and silencing that is controlled by low doses of the smoking cessation drug varenicline. We then synthesized subnanomolar-potency agonists, called uPSEMs, with high selectivity for the chemogenetic receptors. uPSEMs and their receptors were characterized in brains of mice and a rhesus monkey by in vivo electrophysiology, calcium imaging, positron emission tomography, behavioral efficacy testing, and receptor counterscreening. This platform of receptors and selective ultrapotent agonists enables potential research and clinical applications of chemogenetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.